25. Kunz C, Focke F, Saito Y, Schuermann D, Lettieri T, et al. (2009) Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5- fluorouracil. PLoS Biol 7: e1000091. doi:10.1371/journal.pbio.1000091. 26. Sansom OJ, Zabkiewicz J, Bishop SM, Guy J, Bird A, et al. (2003) MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 22: 7130–7136. 27. Li L, Berger SH, Wyatt MD (2004) Involvement of base excision repair in response to therapy targeted at thymidylate synthase. Mol Cancer Ther 3: 747–753. 28. McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM, 3rd (2009) Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res 7: 897–906. 29. Fischer JA, Muller-Weeks S, Caradonna SJ (2006) Fluorodeoxyuridine modulates cellular expression of the DNA base excision repair enzyme uracil- DNA glycosylase. Cancer Res 66: 8829–8837. 30. An Q, Robins P, Lindahl T, Barnes DE (2007) 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res 67: 940–945. 31. Luo Y, Walla M, Wyatt MD (2008) Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase. DNA Repair (Amst) 7: 162–169. 32. Andersen S, Heine T, Sneve R, Konig I, Krokan HE, et al. (2005) Incorporation of dUMP into DNA is a major source of spontaneous DNA damage, while excision of uracil is not required for cytotoxicity of fluoropyrimidines in mouse embryonic fibroblasts. Carcinogenesis 26: 547–555. 33. Grogan BC, Parker JB, Guminski AF, Stivers JT (2011) Effect of the Thymidylate Synthase Inhibitors on dUTP and TTP Pool Levels and the Activities of DNA Repair Glycosylases on Uracil and 5-Fluorouracil in DNA. Biochemistry 50: 618–627. 34. Welsh SJ, Hobbs S, Aherne GW (2003) Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition. Eur J Cancer 39: 378–387. 35. Pettersen HS, Visnes T, Vagbo CB, Svaasand EK, Doseth B, et al. (2011) UNG- initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation. Nucleic Acids Res 39: 8430–8444. 36. Meyers M, Hwang A, Wagner MW, Boothman DA (2004) Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 44: 249–264. 37. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA (2001) Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61: 5193–5201. 38. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, et al. (2005) DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 280: 5516–5526. 39. Sinicrope FA, Sargent DJ (2009) Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21: 369–373. 40. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP- ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123–134. 41. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, et al. (2010) Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. J Clin Oncol 28: 2512–2519. 42. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245–251. 43. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235–244. 44. Muggia FM, Liu PY, Alberts DS, Wallace DL, O’Toole RV, et al. (1996) Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy–a randomized phase II study by the Southwest Oncology Group. Gynecol Oncol 61: 395–402. 45. Israel VK, Jiang C, Muggia FM, Tulpule A, Jeffers S, et al. (1995) Intraperitoneal 5-fluoro-29-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol 37: 32–38. 46. The Cancer Genome Atlas Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609–615. 47. Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol 6: 479–507. 48. Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138: 2073–2087.e3. 49. Kamphuis JT, Huider MC, Ras GJ, Verhagen CA, Kateman I, et al. (1995) High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer. Cancer Chemother Pharmacol 37: 190–192. 50. Morgan RJ, Jr., Speyer J, Doroshow JH, Margolin K, Raschko J, et al. (1995) Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels. Gynecol Oncol 58: 79–85. PARP Inhibitors Sensitize to Floxuridine 51. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, et al. (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N9-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308–4312. 52. Wang Y, Qin J (2003) MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci U S A 100: 15387–15392. 53. Casper AM, Durkin SG, Arlt MF, Glover TW (2004) Chromosomal instability at common fragile sites in Seckel syndrome. Am J Hum Genet 75: 654–660. 54. Luo H, Chan DW, Yang T, Rodriguez M, Chen BP, et al. (2004) A new XRCC1-containing complex and its role in cellular survival of methyl methanesulfonate treatment. Mol Cell Biol 24: 8356–8365. 55. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494–498. 56. Huntoon CJ, Nye MD, Geng L, Peterson KL, Flatten KS, et al. (2010) Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway. Cancer Res 70: 8642–8650. 57. Wagner JM, Karnitz LM (2009) Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharmacol 76: 208–214. 58. Li HR, Shagisultanova EI, Yamashita K, Piao Z, Perucho M, et al. (2004) Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin. Cancer Res 64: 4760–4767. 59. Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15: 2177–2196. 60. Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, et al. (2005) Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68: 1636–1644. 61. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, et al. (2004) Identification and characterization of a novel and specific inhibitor of the ataxia- telangiectasia mutated kinase ATM. Cancer Res 64: 9152–9159. 62. Berger SH, Pittman DL, Wyatt MD (2008) Uracil in DNA: consequences for carcinogenesis and chemotherapy. Biochem Pharmacol 76: 697–706. 63. Ingraham HA, Tseng BY, Goulian M (1980) Mechanism for exclusion of 5- fluorouracil from DNA. Cancer Res 40: 998–1001. 64. Mauro DJ, De Riel JK, Tallarida RJ, Sirover MA (1993) Mechanisms of excision of 5-fluorouracil by uracil DNA glycosylase in normal human cells. Mol Pharmacol 43: 854–857. 65. Kavli B, Sundheim O, Akbari M, Otterlei M, Nilsen H, et al. (2002) hUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup. J Biol Chem 277: 39926–39936. 66. Petronzelli F, Riccio A, Markham GD, Seeholzer SH, Genuardi M, et al. (2000) Investigation of the substrate spectrum of the human mismatch-specific DNA N- glycosylase MED1 (MBD4): fundamental role of the catalytic domain. J Cell Physiol 185: 473–480. 67. Baker D, Liu P, Burdzy A, Sowers LC (2002) Characterization of the substrate specificity of a human 5-hydroxymethyluracil glycosylase activity. Chem Res Toxicol 15: 33–39. 68. Petronzelli F, Riccio A, Markham GD, Seeholzer SH, Stoerker J, et al. (2000) Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase. J Biol Chem 275: 32422–32429. 69. Fischer F, Baerenfaller K, Jiricny J (2007) 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology 133: 1858–1868. 70. Turner DP, Cortellino S, Schupp JE, Caretti E, Loh T, et al. (2006) The DNA N-glycosylase MED1 exhibits preference for halogenated pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine. Cancer Res 66: 7686–7693. 71. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, et al. (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA- damaging agents in preclinical tumor models. Clin Cancer Res 13: 2728–2737. 72. Liu X, Shi Y, Guan R, Donawho C, Luo Y, et al. (2008) Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res 6: 1621–1629. 73. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, et al. (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1: 315–322. 74. Papadopoulos N, Nicolaides NC, Liu B, Parsons R, Lengauer C, et al. (1995) Mutations of GTBP in genetically unstable cells. Science 268: 1915–1917. 75. Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, et al. (1995) Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 55: 3721–3725. 76. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer Statistics, 2009. CA Cancer J Clin 60: 277–300. 77. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, et al. (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroen- terology 117: 123–131. 78. Bracht K, Nicholls AM, Liu Y, Bodmer WF (2010) 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. Br J Cancer 103: 340–346. PLoS ONE | www.plosone.org 9 December 2011 | Volume 6 | Issue 12 | e28862